IBDEI191 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22133,2)
 ;;=^269587
 ;;^UTILITY(U,$J,358.3,22134,0)
 ;;=397.0^^125^1387^75
 ;;^UTILITY(U,$J,358.3,22134,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22134,1,4,0)
 ;;=4^397.0
 ;;^UTILITY(U,$J,358.3,22134,1,5,0)
 ;;=5^Rheumatic Disease Tricuspid Valve
 ;;^UTILITY(U,$J,358.3,22134,2)
 ;;=^35528
 ;;^UTILITY(U,$J,358.3,22135,0)
 ;;=414.3^^125^1387^17
 ;;^UTILITY(U,$J,358.3,22135,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22135,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,22135,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,22135,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,22136,0)
 ;;=414.4^^125^1387^16
 ;;^UTILITY(U,$J,358.3,22136,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22136,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,22136,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,22136,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,22137,0)
 ;;=425.11^^125^1387^60
 ;;^UTILITY(U,$J,358.3,22137,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22137,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,22137,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,22137,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,22138,0)
 ;;=425.18^^125^1387^59
 ;;^UTILITY(U,$J,358.3,22138,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22138,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,22138,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,22138,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,22139,0)
 ;;=V12.55^^125^1387^54
 ;;^UTILITY(U,$J,358.3,22139,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22139,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,22139,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,22139,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,22140,0)
 ;;=454.9^^125^1387^84
 ;;^UTILITY(U,$J,358.3,22140,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22140,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,22140,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,22140,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,22141,0)
 ;;=271.3^^125^1388^11
 ;;^UTILITY(U,$J,358.3,22141,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22141,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,22141,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,22141,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,22142,0)
 ;;=611.1^^125^1388^16
 ;;^UTILITY(U,$J,358.3,22142,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22142,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,22142,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,22142,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,22143,0)
 ;;=704.1^^125^1388^17
 ;;^UTILITY(U,$J,358.3,22143,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22143,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,22143,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,22143,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,22144,0)
 ;;=251.2^^125^1388^30
 ;;^UTILITY(U,$J,358.3,22144,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22144,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,22144,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,22144,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,22145,0)
 ;;=253.2^^125^1388^34
 ;;^UTILITY(U,$J,358.3,22145,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22145,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,22145,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,22145,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,22146,0)
 ;;=733.00^^125^1388^43
 ;;^UTILITY(U,$J,358.3,22146,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22146,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,22146,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,22146,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,22147,0)
 ;;=278.00^^125^1388^40
 ;;^UTILITY(U,$J,358.3,22147,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,22147,1,4,0)
 ;;=4^278.00
 ;;
 ;;$END ROU IBDEI191
